Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIMPONI to Arrest β-cell Loss in Type 1 Diabetes
2021-000189-13Phase 2
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of golimumab in diabetes mellitus type 1 (T1D), sponsored by Janssen Pharmaceutical. Primary endpoint: MMTT-stimulated 4-hour C-peptide AUC at Week 52.
02
Drugs
golimumab
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2021-000189-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000189-13.